

Didimoticho, 26/09/2025

PRESS RELEASE**Interim Financial Statements of EVROFARMA Group of Companies**

Evrofarma Group of Companies, staying true to its long-standing commitment to the production of high-quality dairy products with sustainable development as its main focus, announces its financial results for the first half of fiscal year 2025.

The Company reported increased turnover and improved operational efficiency. Its performance was positively impacted by the uninterrupted operation of its production units and the strategic adaptation of its sales policy to prevailing market conditions. Improved production and animal welfare indicators at the Group's subsidiary, Campus, contributed significantly to the enhancement of its gross profit margin. The Company's earnings were further strengthened by an amount of €1,008 thousand, following a dividend distribution from the subsidiary.

The consolidated turnover amounted to €24,324 thousand, compared to €21,645 thousand in the corresponding period, representing a 12% increase, while company sales increased by 11.5%, amounting to €23,288 thousand, compared to €20,883 thousand in the same period of the previous year. This growth was primarily driven by increased sales in the yogurt category. International sales (yogurt and PDO feta) amounted to €7,022 thousand, compared to €4,463 thousand in the previous year, marking a 57% increase.

The consolidated gross profit amounted to €5,970 thousand, and the company gross profit to €4,111 thousand, compared to €5,248 thousand and €3,769 thousand respectively in the same period last year, reflecting increases of 14% and 9%, respectively.

Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to €3,350 thousand compared to €3,223 thousand, representing an improvement of 4%. Company EBITDA stood at €1,537 thousand versus €1,775 thousand, marking a decrease of 13% compared to the same period last year.

Consolidated earnings before tax amounted to €2,327 thousand compared to €1,840 thousand, reflecting an improvement of 26%. Company earnings before tax reached €1,686 thousand versus €1,566 thousand in the corresponding period of 2024, marking an increase of 8%.

Consolidated net earnings after tax amounted to €1,811 thousand compared to €1,401 thousand, reflecting an improvement of 29%. Company net earnings after tax reached €1,538 thousand versus €1,416 thousand in the corresponding period of 2024, marking an increase of 9%.

During the first half of the year, investments amounting to €2.3 million and investment advances of €0.7 million were implemented, as part of the Company's two-year investment program totaling €10 million. The largest share, exceeding €1.5 million, was invested in next-generation milk processing equipment featuring advanced automation and production control systems, €0.3 million was invested in improvement of general services, and €1 million was invested in the expansion of the strained yogurt production line.

Net debt decreased to €11,042 thousand from €13,425 thousand at the end of fiscal year 2024, marking a reduction of 18%, while the Group maintains strong liquidity, with cash and cash equivalents exceeding €7.5 million.

Management remains cautiously optimistic regarding the remainder of the 2025 fiscal year.

Published on 26/09/2025, after the close of the Athens Stock Exchange session.

The Interim Financial Statements will be available online on:

- Company's website <http://www.evrofarma.gr>
- ATHEX Group website <http://www.athexgroup.gr>.

